David Smoller is a serial entrepreneur, life sciences executive, and investor who has founded, built, and exited multiple biotechnology companies and serves on the boards of several technology and life sciences companies. He is an Entrepreneur in Residence at BioGenerator Ventures and Washington University’s New Ventures group.
Dave co-founded Canopy Biosciences in 2016 and helped grow the company from two founders to more than 50 employees before its acquisition by Bruker Corporation (NASDAQ: BRKR) in 2020.
Previously, Dave was Founder and CEO of SAGE Labs, a gene-editing company acquired by Horizon Discovery in 2014. Following the acquisition, he served as Chief Business Officer and Board Member of Horizon Discovery through 2015.
From 2004 to 2012, Dave held several senior leadership roles at Sigma-Aldrich, including Chief Scientific Officer, President of the Research Biotech Business Unit, and Vice President of R&D.
Earlier, Dave was Founder and CEO of ProteoPlex, which was acquired by EMD Biosciences/Merck KGaA in 2003, after which he served as Vice President of Corporate Development at EMD. He was also Founder and President of Genome Systems, acquired by Incyte in 1996. He remained with Incyte through 2001, ultimately serving as Senior Vice President and head of its genomics business.
Dave earned his PhD in Molecular Biology and BS in Biology from Emory University and completed postdoctoral fellowships at Washington University’s Drosophila Genome Project and Monsanto Corporation.
The background described above reflects this individual’s professional experience, including prior roles, outside activities, and involvement with Cultivation Capital portfolio companies. It does not represent the investment performance of any Cultivation Capital fund and should not be relied upon as an indication of future results.
